Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model

Abstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor to...

Full description

Bibliographic Details
Main Authors: Tomoki Fukuyama, Sarah Ehling, Jenny Wilzopolski, Wolfgang Bäumer
Format: Article
Language:English
Published: BMC 2018-07-01
Series:BMC Pharmacology and Toxicology
Subjects:
IgE
Online Access:http://link.springer.com/article/10.1186/s40360-018-0232-3
id doaj-4b4f6f17c2564633a111e56149d1b4e7
record_format Article
spelling doaj-4b4f6f17c2564633a111e56149d1b4e72020-11-25T00:11:29ZengBMCBMC Pharmacology and Toxicology2050-65112018-07-011911810.1186/s40360-018-0232-3Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis modelTomoki Fukuyama0Sarah Ehling1Jenny Wilzopolski2Wolfgang Bäumer3Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityDepartment of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State UniversityAbstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. Methods The effect of topically administered HOCl (0.1%) in gel was compared to a topical formulation of tofacitinib (0.5%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice as well as itch behaviour. NC/Nga mice were sensitized with house dust mite allergen. After reaching visible lesions, mice were treated either topically with HOCl or tofacitinib or gel vehicle for 17 days. After termination of the study, dorsal root ganglia were isolated for ex vivo stimulation and skin samples were taken for cytokine determination in inflamed skin. Results When administered onto lesional skin of NC/Nga mice, both HOCl and tofacitinib reduced lesions and scratching behaviour. The reduced inflammatory response by HOCl and tofacitinib treatment was demonstrated by diminished inflammatory cytokines in affected skin tissue from NC/Nga mice. Dorsal root ganglia neurons re-stimulated with a range of mediators of itch showed a reduced response compared to the vehicle control mice, when isolated from tofacitinib or HOCl treated mice. Conclusions These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis.http://link.springer.com/article/10.1186/s40360-018-0232-3Atopic dermatitisDorsal root gangliaHypochlorous acidTofacitinibIgEIL-4
collection DOAJ
language English
format Article
sources DOAJ
author Tomoki Fukuyama
Sarah Ehling
Jenny Wilzopolski
Wolfgang Bäumer
spellingShingle Tomoki Fukuyama
Sarah Ehling
Jenny Wilzopolski
Wolfgang Bäumer
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
BMC Pharmacology and Toxicology
Atopic dermatitis
Dorsal root ganglia
Hypochlorous acid
Tofacitinib
IgE
IL-4
author_facet Tomoki Fukuyama
Sarah Ehling
Jenny Wilzopolski
Wolfgang Bäumer
author_sort Tomoki Fukuyama
title Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
title_short Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
title_full Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
title_fullStr Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
title_full_unstemmed Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
title_sort comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model
publisher BMC
series BMC Pharmacology and Toxicology
issn 2050-6511
publishDate 2018-07-01
description Abstract Background Topical administration of PR022, 0.05% hypochlorous acid (HOCl) in gel has been demonstrated to be beneficial in a chronic murine atopic dermatitis model. In a follow up study we tested a higher concentration (0.1%) of PR022 HOCl gel in comparison to the Janus kinase inhibitor tofacitinib, both of which are currently in clinical phase studies for treatment of human atopic dermatitis. Methods The effect of topically administered HOCl (0.1%) in gel was compared to a topical formulation of tofacitinib (0.5%) in a therapeutic setting on atopic dermatitis-like lesions in NC/Nga mice as well as itch behaviour. NC/Nga mice were sensitized with house dust mite allergen. After reaching visible lesions, mice were treated either topically with HOCl or tofacitinib or gel vehicle for 17 days. After termination of the study, dorsal root ganglia were isolated for ex vivo stimulation and skin samples were taken for cytokine determination in inflamed skin. Results When administered onto lesional skin of NC/Nga mice, both HOCl and tofacitinib reduced lesions and scratching behaviour. The reduced inflammatory response by HOCl and tofacitinib treatment was demonstrated by diminished inflammatory cytokines in affected skin tissue from NC/Nga mice. Dorsal root ganglia neurons re-stimulated with a range of mediators of itch showed a reduced response compared to the vehicle control mice, when isolated from tofacitinib or HOCl treated mice. Conclusions These data indicate a similar beneficial potential of topical high dose PR022 HOCl (0.1%) in gel and tofacitinib, in a translational murine model of atopic dermatitis.
topic Atopic dermatitis
Dorsal root ganglia
Hypochlorous acid
Tofacitinib
IgE
IL-4
url http://link.springer.com/article/10.1186/s40360-018-0232-3
work_keys_str_mv AT tomokifukuyama comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel
AT sarahehling comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel
AT jennywilzopolski comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel
AT wolfgangbaumer comparisonoftopicaltofacitiniband01hypochlorousacidinamurineatopicdermatitismodel
_version_ 1725403741439393792